The Pfizer SAM-competitive PRMT5 inhibitor, PF-06939999 is a Ph. I clinical candidate in dose escalation in solid tumors. Ph. I data has been reported showing signs of early efficacy with cytopenias as common adverse events. This is in agreement with Ph. I data that was recently reported for a JNJ SAM-competitive PRMT5 inhibitor in [...]
< 1 minute read
Dec. 20, 2021
PF-06939999 is a SAM-Competitive PRMT5 Inhibitor
PF-06939999
oral SAM-competitive PRMT5 inhibitor Ph. I candidate for solid tumors (adv. or met.) SBDD utilizing PRMT5:MEP50 w/ A9145C Molecular Cancer Therapy Pfizer Oncology
Loading...
